OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2009 & 2005 Program Project Development Grant Recipient – Andrew Berchuck

Andrew Berchuck, M.D.
Duke University
International Ovarian Cancer Association Consortium: Finding Genetic Markers of Ovarian Cancer Using Polymorphisms

Andrew Berchuck, MD

Project Summary

While some ovarian cancers arise in women with inherited mutations in the BRCA1 or BRCA2 genes, the genetic changes responsible for most ovarian cancers, which are not inherited, remains unknown. Understanding these latter genetic changes could lead to better diagnostics and treatment for the disease. Dr. Berchuck is the Principal Investigator of the International Ovarian Cancer Association Consortium (OCAC)—that includes researchers at 19 institutions in the U.S., the U.K., and Australia–which aims to find subtle genetic changes, called polymorphisms, that may exist and predispose women to ovarian cancer. Because such polymorphism studies require large populations to compare women with ovarian cancer to woman who have not had the disease, the International OCAC was founded to facilitate the collaboration to get study subjects. The other goals of the OCAC are: finding ovarian cancer-susceptibility polymorphisms, understanding the relationship between polymorphisms and hormone pathways and investigating the links between known risk factors for ovarian cancer and polymorphisms.


Andrew Berchuck, M.D. is Co-Director of the Duke Comprehensive Cancer Center Breast/Ovarian Cancer Program. He also serves as the Director of Gynecologic Cancer Research.

Dr. Berchuck has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) using microarrays to define molecular signatures that are predictive of clinical phenotypes and response to targeted biological therapies.

Dr. Berchuck attended medical school and received his Obstetrics and Gynecology residency training at Case Western Reserve University in Cleveland, Ohio. His research and clinical training in Gynecologic Oncology was completed at UT Southwestern in Dallas, Texas and Memorial Sloan-Kettering Cancer Center in New York City.

Selected Recent Press
Catching Ovarian Cancer Early May Miss Aggressive Tumors

New Gene Mutation for Ovarian Cancer Found (download press release)